Abstract:Purpose Fibroblast activation protein is one of the most attractive targets for tumor diagnosis and therapy. There have been many successful clinical translations with small molecules and peptides, yet only a few anti-FAP antibody diagnostic or therapeutic agents have been reported. Antibodies often feature good tumor selectivity and long tumor retention, which may be a better-match with therapeutic radionuclides (e.g., 177 Lu, 225 Ac) for cancer therapy. Here we report a 177 Lu-labeled anti-FAP antibody, PKU525, as a therapeutic radiopharmaceutical for FAP-targeted radiotherapy. Methods The anti-FAP antibody is produced as a derivative of sibrotuzumab. The pharmacokinetics and blocking study are performed with 89 Zr-labeled antibody by PET imaging. The conjugation strategies have been screened and tested with SPECT imaging through 177 Lu-labeling. The biodistribution and radiotherapy studies are performed on 177 Lu-labeled anti-FAP antibody in NU/NU mice-bearing HT-1080-FAP tumors. Results A multiple time-point PET imaging study shows that the tumor accumulation of [ 89 Zr]Zr-DFO-PKU525 is intense, selective, and relatively rapid. The time activity curve indicates that the tumor uptake continually increases until reaches the highest uptake (SUVmax = 18.4 ± 2.3, n = 4) at 192 h, then gradually declines. Radioactivity rapidly cleared from the blood, liver, and other major organs, resulting in high tumor-to-background ratios. An in vivo blocking experiment suggests that [ 89 Zr]Zr-DFO-PKU525 is FAP-specific and the uptake in FAP-negative tumors is almost negligible. Ex vivo biodistribution study shows that the tumor uptake of [ 177 Lu]Lu-DOTA-NCS-PKU525 is 23.04 ± 5.11% ID/g, 33.2 ± 6.36% ID/g, 19.87 ± 6.84% ID/g and 19.02 ± 5.90% ID/g at 24 h, 96 h, 168 h, and 240 h after injection ( n = 5), which is corroborated with the PET imaging. In therapeutic assays, multiple doses of [ 177 Lu]Lu-DOTA-NCS-PKU525 have been tested in tumor-bearing mice, and the data suggests that 3.7 MBq may be sufficient to completely suppress the tumor growth in mice without showing observable side effects. Conclusion A FAP-targeted antibody-radionuclide conjugate was developed and evaluated in vitro and in vivo. Its tumor accumulation is rapid and high with a clean background. It remarkably suppresses the tumors in mice while the side effect is almost negligible, showing that it is promising for further clinical translational studies.

Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy

Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

Synthesis and Preclinical Evaluation of Novel 18F-Labeled Fibroblast Activation Protein Tracers for Positron Emission Tomography Imaging of Cancer-Associated Fibroblasts.

Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-based Small Molecules.

Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts

Development of an FAP-Targeted PET Probe Based on a Novel Quinolinium Molecular Scaffold

Synthesis and Preclinical Evaluation of Novel 99Mtc-Labeled FAPI-46 Derivatives with Significant Tumor Uptake and Improved Tumor-to-Nontarget Ratios.

Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging

Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [68Ga]ga-Fapi-fuscc-ii.

An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

Preparation and Bioevaluation of <SUP>99m</SUP>Tc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein

Development of Ibuprofen-Modified Fibroblast Activation Protein Radioligands to Improve Cancer Therapy

Rational modifications on N -(4-quinolinoyl)-Gly-2-cyanopyrrolidine to develop fibroblast activation protein-targeted radioligands with improved affinity and tumor uptake

18F- or 177Lu-Labeled Bivalent Ligand of Fibroblast Activation Protein with High Tumor Uptake and Retention.

Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3